We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019.
- Authors
Reza Hashemian, Seyed; Farhadi, Tayebeh
- Abstract
In coronavirus disease 2019 (COVID-19), the formation of cytokine storm may have a role in worsening of the disease. By attaching the cytokines like interleukin-6 to the cytokine receptors on a cell surface, Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway will be activated in the cytoplasm lead to hyperinflammatory conditions and acute respiratory distress syndrome. Inhibition of JAK/STAT pathway may be useful to prevent the formation of cytokine storm. Tofacitinib is a pan inhibitor of JAKs. In this review, the main characteristics of tofacitinib and its usefulness against COVID-19 pneumonia were reviewed. Tofacitinib may be a hopeful therapeutic candidate against COVID-19 respiratory injury since it inhibits a range of inflammatory pathways. Hence, the agent may be considered a potential therapeutic against the post-COVID-19 respiratory damage. Compared to other JAK inhibitors (JAKi), the administration of tofacitinib in COVID-19 patients may be safer and more effective. Other JAKi such as baricitinib are related to severe adverse events such as thrombotic events compared to more common side effects of tofacitinib.
- Subjects
COVID-19; THYROID crisis; CELL receptors; ADULT respiratory distress syndrome; INTERLEUKIN-6 receptors; CYTOKINE receptors
- Publication
International Journal of Critical Illness & Injury Science, 2023, Vol 13, Issue 4, p192
- ISSN
2229-5151
- Publication type
Article
- DOI
10.4103/ijciis.ijciis_27_23